To determine the relationship between central venous pressure (CVP) and renal function in patients with acute heart failure (AHF) presenting to the emergency department.
Introduction
Renal impairment is common in patients with acute heart failure (AHF) and is an important independent predictor of poor survival and (re)hospitalization. 1 -3 Both impaired renal function at baseline and in-and out-hospital worsening renal function (WRF) are strongly associated with unfavourable outcomes. 1, 2, 4 Renal arterial perfusion had been shown to be the major determinant of renal dysfunction, 5 but recent data also suggest an important relationship between renal dysfunction and venous congestion. Elevated central venous pressure (CVP) has been shown to be associated with impaired renal function, rehospitalization for heart failure, and mortality in a broad spectrum of patients with cardiovascular diseases including acute and chronic heart failure. 6 -9 It has been † These authors contributed equally to this work.
assumed that venous congestion with increased renal afterload and renal interstitial pressure might lead to the development of 'congestive kidney failure' but the pathophysiology is complex and still unsatisfactorily understood. 10, 11 Using the recently established non-invasive technique of compression sonography of a forearm vein to measure CVP, 12, 13 we aimed to close two important gaps in our knowledge of the cardiorenal syndrome. First, without the need for time-consuming and invasive central catheter placement, we are able to measure CVP not only in patients with advanced AHF requiring intensive care support 8 but also in an unselected population of patients presenting to the emergency department (ED) with AHF. Secondly, already established intensive care therapy may have altered the initial CVP values in previous studies and thus the measurement of CVP very early in the course of hospitalization in our study might reduce time bias, e.g. by already effective therapy. Central venous pressure at ED presentation seems to be an independent predictor of rehospitalization in patients with decompensated heart failure but data on renal function have not been analysed in detail so far. 9 In summary, using the recently established compression sonography of a forearm vein to measure CVP at ED presentation, we aimed to further examine the importance of CVP for impaired renal function in an unselected population of patients hospitalized due to AHF.
Methods

Patients, data collection, and renal assessment
Patients presenting with AHF to the ED of the University Hospital of Basel, Switzerland, between April 2006 and November 2009 were analysed. To be eligible for enrolment, patients had to be over 18 years old and present with all three of the following signs of AHF at presentation: dyspnoea at rest or on minor exertion, chest radiographic signs compatible with AHF, and a serum B-type natriuretic peptide (BNP) level exceeding 500 pg/mL. All eligible patients were enrolled whenever CVP measurements were promptly available (8:00 a.m. -6:00 p.m.). To avoid the influence of therapy on initial CVP, measurement within 1 h after enrolment was targeted. Patients underwent an initial clinical assessment that included clinical history, physical examination, electrocardiography, pulse oximetry, blood tests including BNP, chest X-ray, non-invasive ultrasound measurement of CVP at presentation to the ED, and echocardiography (when indicated). Before discharge, the physical examination, blood tests, and measurement of CVP were repeated.
In addition to baseline and discharge values, sequential serum creatinine and blood urea nitrogen values were obtained 24, 48, 72, 96 h, and 6 days after admission. Estimated glomerular filtration rate (eGFR) was calculated using the four-variable modification of diet in renal disease (MDRD) equation.
14 Consistent with several previous studies, 8, 15, 16 we defined WRF as an increase in serum creatinine of ≥0.3 mg/dL (26.5 mmol/L) at any time point during hospitalization. Three main analyses were performed to examine the relationship between CVP and renal function. First, the association between CVP at presentation and eGFR at presentation was analysed. Secondly, the association between CVP at discharge and eGFR at discharge was analysed. Finally, the association between initial CVP and WRF during the course of hospitalization was examined.
The study was approved by the Ethics Committee of the University of Basel. Patients gave written informed consent to participate in the study. The study conformed to the principles outlined in the Declaration of Helsinki.
Non-invasive measurement of central venous pressure
Central venous pressure measurement was performed using an HDI 5000 or iU22 duplex device (Philips, Best, The Netherlands) with a 12-5 MHz linear array transducer (SonoCT, XRes) and an attached pressure manometer (PPM0310, Baumann, Muensingen, Switzerland). The manometer consists of a translucent silicon membrane (MVQ, Angst and Pfister AG, Zurich, Switzerland) connected to a commercially available pressure meter (Bourdon Haenni AG, Jegenstorf, Switzerland) with flexible pressure tubing. Patients were placed in a supine position in a temperature-controlled room and measurement was done with the forearm placed on the bed. After zero adjustment, slowly increasing pressure was applied by the transducer until complete compression of the selected superficial forearm vein (preferentially the distal cephalic vein) was obtained. The pressure when the vein completely collapsed corresponds to the intravasal venous pressure and was measured continuously. The difference between the level of the sonographic measurement point and the right atrial level was subtracted from the crude value for correction of the blood column height. Non-invasive CVP can be adequately obtained within ,4 min. 13 In healthy subjects as well as in intensive care unit patients, a high correlation and negligible difference between the non-invasive and the invasive measurement of CVP has been demonstrated.
12,13
Statistical analysis an SBP , 110 mmHg was classified 'low SBP'. Statistical significance was set at a two-tailed probability level of ,0.05.
Results
Non-invasive measurement of CVP was performed in 141 patients within 14 min (median; inter-quartile range: 12, 17 min) after enrolment. One patient (0.7%) was excluded from the analysis because no suitable peripheral vein could be detected to perform the CVP measurement. Baseline characteristics of the remaining 140 patients at presentation are displayed in the first column of Table 1 .
Central venous pressures at presentation and discharge were 13.2 + 6.9 and 7.6 + 6.0 cmH 2 O, respectively. No correlation between CVP and eGFR at presentation or CVP and eGFR at discharge was observed (r ¼ 0.005, P ¼ 0.419 and r ¼ 0.013, P ¼ 0.131, respectively) ( Figure 1A and B). As demonstrated in Figure 3A , the association between low CVP and WRF progressively declined during the course of hospitalization, and as early as 48 h after presentation, the association between low CVP and WRF was no longer statistically significant. The AUC for CVP and all-time in-hospital WRF was similarly nonsignificant (0.531, P ¼ 0.625). Nevertheless, analysing the incidence of WRF between 24 and 96 h after admission, the highest absolute and relative incidence of WRF was observed in patients with CVP in the top tertile [7 (14%) compared with 2 (6%) in the middle and 4 (8%) in the lowest CVP tertile]. Figure 3B displays the cumulative percentage of patients with WRF according to SBP. No significant association between SBP and the incidence of WRF was detected. Tables 1 and 2 also show the results of the univariate and multivariate analyses with regard to all-time in-hospital WRF. b-Blocker medication was significantly associated with WRF during hospitalization in univariate analysis and a trend was observed with regard to age, diuretic medication, lower haemoglobin, and urea. In the multivariate analysis, no significant association was detected. Table 3 summarizes the clinical parameters and medication at discharge. During hospitalization, a significant reduction in CVP and body weight was observed (26.1 + 7.1 cmH 2 O and 23.9 + 5.0 kg, respectively), but CVP and body weight reduction by itself did not predict WRF (AUC ¼ 0.606, P ¼ 0.144 and AUC ¼ 0.565, P ¼ 0.333, respectively). Patients with WRF were less likely to receive diuretics at discharge but the frequency of prescription was still high (82 vs. 92%, P ¼ 0.047).
Discussion
Using a recently established non-invasive technique of CVP measurement, we were able to study the relationship between CVP and renal function in AHF patients starting at presentation to the ED.
We report five major findings. First, CVP at presentation and discharge did not correlate to eGFR. Secondly, in patients with low SBP, high CVP at presentation and discharge was significantly associated with lower eGFR. Thirdly, in patients with normal to high SBP, CVP seems to have no effect on eGFR. Fourthly, low CVP at presentation was associated with the development of WRF within 24 h after admission but, fifthly, this association declined during the course of hospitalization with a higher incidence of WRF between 24 and 96 h after admission in patients with CVP in the top tertile.
Renal dysfunction (at baseline and WRF during hospitalization) is a strong and independent predictor of cardiovascular outcome in the general population but also in patients with heart failure. 1, 4, 17 It is commonly observed that coexisting renal dysfunction may complicate the treatment of heart failure and that the use of diuretics often alleviate congestion at the cost of renal function, especially during the initial days after treatment for AHF. 5, 8, 10, 18, 19 In-hospital WRF has been reported to occur in 11 -40% of the patients with heart failure. 4, 8 This substantial difference may be explained not only by different patient populations but also by differences in the definition and assessment of WRF. In our study with systematic sequential assessment of renal function, in-hospital WRF was observed in 36% of the patients, which is a similarly high percentage of WRF as in patients with advanced AHF monitored in an intensive care setting. 8 Using only baseline and discharge creatinine values, WRF occurred in 'only' 22% of our patients underscoring the need for thorough sequential assessment of creatinine levels when referring to true in-hospital WRF and underlying pathophysiological mechanisms. The pathophysiology of renal impairment in heart failure is complex and multifactorial with decreased renal perfusion and venous congestion representing major contributing factors. Although, at first sight, baseline CVP in our study was not associated with initial eGFR, our data suggest two important different pathophysiological components in the context of CVP and impaired renal function in AHF.
First, low CVP at presentation was associated with WRF within 24 h, indicating that these patients are at risk for accelerated renal function loss when heart failure therapy is (re)established and escalated. Clinical examination has been shown to be an unreliable tool to assess CVP, 20 -22 when treatment was directed at lowering invasively measured right atrial pressure, whereas it did worsen in the group where treatment was guided by clinical assessment. 23 Metra et al. 24 recently
published the results of a prospective study in which 318 patients with AHF were enrolled. In accordance with our results, no significant association of entry GFR with WRF and diuretic medication at entry was observed. Apparently, neither GFR nor diuretic medication at presentation reliably predicts the reserve of the kidneys to tolerate the therapies initiated during AHF. Nevertheless, subanalysis revealed that patients with WRF in the first 24 h had received significant higher dosages of i.v. furosemide during the first 24 h after admission. In addition, a trend towards more diuretic medication in patients with in-hospital WRF (P ¼ 0.058) was also observed in our smaller cohort. The fact that less diuretics were prescribed at discharge in our patients with WRF might indicate that the treating physician attributed the WRF to the usage of diuretics and therefore paused diuretics, at least temporarily in these patients. Interestingly, the diuretic dosages (especially the initial i.v. furosemide dosage) in patients with initially low or high CVP did not differ. Non-invasive assessment of CVP by compression sonography of a forearm vein may thus be a promising tool to fulfil the clinical need to identify patients with low CVP in AHF already in the ED and might help to guide subsequent diuretic therapy. Further evaluation of this critical issue in prospective trials is warranted. Secondly, our data support the hypothesis that impaired renal function is not solely attributable to a fall in cardiac output and volume depletion. The combination of both decreased cardiac output and increased venous pressure in heart failure has already been reported by Stevenson and Perloff, 25 and recent data suggest that CVP is an important haemodynamic factor for impaired renal function, especially in combination with decreased cardiac output. and LVEF , 30% treated with intensive medical therapy. In the patient population with low-output-decompensated heart failure, the presence of venous congestion was the strongest haemodynamic determinant for the development of WRF, whereas in the pulmonary hypertension population, the contribution of CVP to renal impairment seemed to be restricted to patients with reduced cardiac index. We believe that our study results in patients with AHF broaden the validity of the current concept of the co-impact of venous congestion and low cardiac output on renal function. First, by including all patients with AHF presenting to the ED, our patient population represents the full spectrum of AHF patients, with 16% of the patients forwarded to the intensive care unit and the majority (84%) treated in a general ward.
A particular strength of our study is the measurement of CVP at presentation to the ED, thus confounding by already established therapy was limited. For example, in previous studies, the measurement of a high CVP at a later time and its association with WRF in patients with low-output AHF might indicate a degree of therapy resistance in these patients. In contrast, at least in some of our patients with 'untreated' high CVP, elevated CVP was likely to be lowered with relatively low doses of diuretics and accordingly patients were initially at a relatively lower risk of developing WRF. This might explain why patients with high CVP had a relatively low incidence of WRF within the first 24 h but the highest absolute and relative incidence of WRF was between 24 and 96 h. In addition, low BP in combination with high CVP might also indicate potential therapy resistance and explain the comparable observed association of high CVP with WRF in our study. In conclusion, the different effect of CVP on WRF in our study, i.e. the initial association of low CVP with WRF, might be partly explained by our different study population and time of CVP acquisition. The use of this novel technique to measure CVP non-invasively not only has advantages but also poses some major limitations. The 'gold-standard' of CVP measurement using a catheter placed in a central vein was not used. However, non-invasive controlled compression sonography of the forearm has been demonstrated to be accurate for measuring CVP with a high correlation between invasive and non-invasive ultrasound CVP measurement at a wide range of pressures, not only in a highly selected but also in a more generalized setting. The mean difference between invasive and non-invasive measurement has been shown to be negligible (20.1 + 3.5 cmH 2 O). 12, 13 Furthermore, using two easily obtainable haemodynamic parameters (non-invasive CVP and BP) without the need for sophisticated monitoring our results broadens its applicability in real life. Another limitation of our study is its relatively small sample size which precludes advanced analyses (e.g. of multiple BP groups) and the relatively slow recruitment of patients. A correlation between overall CVP and renal function as described by Damman et al. in 2557 patients with a broad spectrum of cardiovascular disease could not be detected in our smaller study, but the reported correlation (r ¼ 20.147) was only modest and of questionable clinical relevance (though of value for hypothesis generating). Thus, we believe that recruitment of more patients would not alter our main results substantially but that further efforts are needed to close the remaining gaps. We did not enrol consecutive patients with AHF and a selection bias may therefore have occurred. The decision for enrolment was made blinded to patients' clinical characteristics and was only limited by the prompt availability of the CVP measurement (ultrasound machine and examiner). In fact, the baseline characteristics of our study population were very similar to the baseline characteristics of a previously published study of 217 patients with AHF presenting at the ED of the University Hospital of Basel over 1 year. 26 Thus, we believe that a relevant selection bias is very unlikely and that on the other hand, our study presents uniquely reliable data due to minimized confounding (therapy) factors. The term 'cardiorenal syndrome' enjoys great popularity in the current literature, although the definition of the cardiorenal syndrome remains fairly imprecise. Our study illustrates that the link between impaired renal function and CVP in patients with AHF is complex and congestion as well as low CVP may contribute to renal impairment. The management of AHF requires a good understanding of the particular haemodynamic conditions of the individual patient. Compression sonography of the forearm may serve, in addition to a basic physical examination including body weight and blood monitoring, as a valuable tool to help tailor therapy (e.g. diuretics) in patients with AHF.
